Neurology
Spinal Muscular Atrophy
~12 min read8 sections
Contents (8)
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder characterized by loss of motor neurons in the anterior horn of the spinal cord, resulting in progressive proximal muscle weakness and atrophy. The disease is caused by mutations in the SMN1 gene (survival motor neuron 1) on chromosome 5q13, leading to deficiency of the SMN protein, which is essential for motor neuron survival and function. SMA is the leading genetic cause of infant mortality, with an incidence of approximately 1 in 10,000 live births and a carrier frequency of 1 in 50. The severity and age of onset vary widely, classified into four types (I–IV) based on the highest motor milestone achieved. Despite historically being a devastating disease, recent advances in disease-modifying therapies have dramatically altered the natural history and prognosis of affected individuals.
The molecular and cellular mechanisms underlying SMA involve:
- SMN Protein Deficiency and Motor Neuron Vulnerability: Loss of SMN1 gene function leads to insufficient SMN protein, which is critical for the assembly and function of small nuclear ribonucleoproteins (snRNPs) and the spliceosome. Motor neurons are uniquely vulnerable to SMN deficiency due to their large size, high metabolic demands, and dependence on SMN for axonal growth and synaptic stability. SMN protein also regulates snRNP biogenesis, affecting the splicing of numerous transcripts, including those encoding proteins involved in neuronal development and survival.
- Neuromuscular Junction and Axonal Dysfunction: SMN deficiency impairs neuromuscular junction (NMJ) stability and acetylcholine receptor (AChR) clustering, leading to synaptic dysfunction. Reduced SMN levels impair axonal transport of critical proteins and organelles, causing accumulation of abnormal proteins and mitochondrial dysfunction. There is selective degeneration of the distal axons of large motor neurons, with proximal muscles being affected before distal muscles due to the greater axonal length and synaptic demands.
- Compensatory SMN2 Gene Expression: While the disease-causing SMN1 deletion/mutation eliminates functional protein production, humans uniquely possess a paralogous SMN2 gene that arises from a duplication event. Due to an intronic nucleotide difference, SMN2 undergoes aberrant splicing, predominantly producing truncated, unstable SMNΔ7 protein that cannot fully compensate. The number of SMN2 gene copies inversely correlates with disease severity, with more copies producing greater amounts of full-length SMN protein and milder phenotypes. This SMN2 dosage effect is the basis for understanding SMA severity classification and for therapeutic targeting strategies.
SMA is caused by and associated with:
- SMN1 Gene Mutation (95% of cases): Homozygous deletion of the SMN1 gene (the most common mutation, accounting for ~95% of SMA cases) or point mutations within SMN1 result in loss of functional SMN protein. The deletion of the 5q13.2 region is predisposed by a complex genomic architecture involving inverted duplications and segmental duplications that facilitate non-allelic homologous recombination.
- SMN2 Gene Copy Number Variation: The number of SMN2 gene copies (typically 1–4 copies in the normal population) is the primary modifier of disease severity. Patients with SMA typically have zero copies of SMN1 but retain SMN2 copies; those with more SMN2 copies produce more full-length SMN protein and have milder disease. This genetic modifier explains the wide phenotypic heterogeneity observed among SMA patients.
- Autosomal Recessive Inheritance Pattern: SMA requires inheritance of two mutant alleles (one from each parent); parents are typically unaffected heterozygous carriers. Genetic counseling and prenatal/preimplantation genetic testing are important considerations for affected families. De novo mutations are exceedingly rare (<1% of cases).
The clinical manifestations vary by SMA type but include:
- Progressive Proximal Muscle Weakness: Weakness begins in lower extremities and hip/pelvic girdle muscles and progresses to shoulder girdle and upper extremity muscles. The pattern is typically symmetrical and proximal, sparing the distal muscles until late in disease. Weakness is progressive but at variable rates depending on SMA type and natural history.
- Hypotonia and Loss of Motor Milestones:
- SMA Type I (infantile; age <6 months): Severe hypotonia, inability to achieve head control, never achieve sitting independently. Presentation typically by 2–3 months of age with poor feeding, weak cry, and apparent floppy infant.
- SMA Type II (intermediate; age 6–12 months): Delayed sitting without support (achieved by 8–10 months), inability to stand or walk independently. Slower progression than Type I.
- SMA Type III (juvenile; age >12 months to early childhood): Ability to walk independently, though with a waddling gait and difficulty with stairs. Progressive loss of ambulation in late childhood/adolescence.
- SMA Type IV (adult-onset): Mild weakness, normal or near-normal achievement of motor milestones, slower progression; symptoms may not manifest until early adulthood.
- Physical Examination Findings:
- Severe proximal muscle weakness with relatively preserved distal strength (classic "reverse distribution")
- Hypotonia and decreased deep tendon reflexes (DTRs may be normal early; diminished with progression)
- Fasciculations (fine tremors, tongue fasciculations in SMA Type I) visible under skin or in muscles; this finding is highly specific for motor neuron disease
- Absence of contractures (unless secondary to immobility)—this distinguishes SMA from muscular dystrophies
- Bell's sign or paradoxical breathing in advanced disease (use of accessory muscles, abdominal paradox)
- Secondary Manifestations:
- Respiratory compromise: Diaphragmatic and intercostal muscle weakness leading to restrictive lung disease, sleep apnea, and ventilatory failure (primary cause of mortality in untreated Type I SMA)
- Feeding and swallowing difficulties: Weakness of jaw, tongue, and pharyngeal muscles; risk of aspiration, poor weight gain
- Scoliosis: Progressive spinal curvature due to weakness of paraspinal muscles, more severe in non-ambulatory patients
- Joint contractures: Secondary to immobility and muscle weakness, particularly in advanced disease
- Cognitive development: Normal (intellectual disability does not occur in classical SMA; patients with cognitive decline should prompt consideration of alternative diagnoses)
The diagnostic approach to SMA is multimodal and includes:
- Genetic Testing (Confirmatory Test of Choice):
- SMN1 gene deletion analysis using quantitative PCR (qPCR) or multiplex ligation-dependent probe amplification (MLPA): Detects homozygous deletion of SMN1 exons 7 and/or 8 in ~95% of SMA cases. Highly sensitive and specific; cost-effective initial screening test.
- SMN1 sequencing: Identifies point mutations, inversions, or complex rearrangements in patients with suspected SMA but negative deletion analysis (accounts for ~5% of cases).
- SMN2 copy number determination: Performed using qPCR or MLPA; important for prognostic stratification and treatment planning. Typical distribution: 1–4 copies (rarely >4).
- Carrier testing: Available for at-risk family members; confirms heterozygous carrier status.
- Electrophysiological Studies:
- Electromyography (EMG): Demonstrates acute and chronic denervation with evidence of motor unit action potential (MUAP) enlargement, reduced recruitment, and positive sharp waves/fibrillation potentials (signs of active denervation). EMG pattern is consistent with motor neuron disease (anterior horn cell pathology).
- Nerve Conduction Studies (NCS): Sensory nerves are completely normal (normal sensory action potentials); motor NCS show normal conduction velocities but reduced amplitudes due to axonal loss. This normal sensory responses with abnormal motor findings helps distinguish SMA from demyelinating neuropathies.
- EMG/NCS helps differentiate SMA from other causes of hypotonia and weakness (e.g., muscular dystrophies, inflammatory myopathies) but is less essential now that genetic testing is widely available.
- Serum Biomarkers:
- Phosphorylated neurofilament heavy chain (pNfH) and phosphorylated tau (p-tau): Elevated in SMA, reflecting neuronal damage and motor neuron degeneration. May serve as biomarkers for disease progression and treatment response, though not standard diagnostic criteria.
- Creatine kinase (CK): Normal or only mildly elevated in SMA, in contrast to muscular dystrophies (which show markedly elevated CK). This finding supports motor neuron pathology rather than primary muscle disease.
- Muscle Biopsy (rarely needed with modern genetic testing):
- Demonstrates neurogenic atrophy pattern: small angular atrophic fibers with relative preservation of type I and II fiber architecture (in contrast to primary myopathies).
- Electron microscopy may show abnormalities in mitochondrial morphology and organization.
- Imaging Studies (supportive but not diagnostic):
- Brain and Spinal Cord MRI: May show anterior horn atrophy or spinal cord atrophy in advanced SMA; helps exclude alternative diagnoses (spinal cord compression, syrinx, structural abnormalities).
- Chest Imaging: Assesses for scoliosis, aspiration, and baseline lung parenchymal changes.
- Diagnostic Criteria (based on clinical and genetic features):
- Homozygous deletion/mutation of SMN1 gene confirmed by genetic testing
- Clinical features consistent with age-appropriate SMA type (progressive proximal muscle weakness, hypotonia, characteristic motor milestones)
- Supportive findings: Normal cognition, normal sensory NCS, motor neuron changes on EMG, elevated neurofilament biomarkers
Modern SMA management has been revolutionized by disease-modifying therapies and includes:
- Disease-Modifying Pharmacotherapy (First-Line):
- Nusinersen (Spinraza; antisense oligonucleotide):
- Mechanism: Antisense oligonucleotide that binds to intronic sequences of SMN2 pre-mRNA, promoting skipping of the intronic region that causes exon 7 exclusion. Results in increased production of full-length functional SMN protein from the SMN2 gene.
- Administration: Intrathecal injection; initial loading phase of 4 doses (days 0, 14, 28, 63) followed by maintenance dosing every 4 months indefinitely.
- Efficacy: Most effective when initiated early (infants), with dramatic improvement in survival and motor function in SMA Type I (previously uniformly fatal by age 2). Also beneficial in Types II–IV but with more variable responses.
- Adverse Effects: Transient CSF pleocytosis, headache, back pain; potential for post-injection transient neurological symptoms.
- Onasemnogene Abeparvovec (Zolgensma; gene replacement therapy):
- Mechanism: Self-complementary adeno-associated virus (scAAV9) vector carrying a functional copy of the SMN1 gene delivered intravenously. Results in one-time expression of SMN protein by transduced motor neurons.
- Administration: Single intravenous infusion; children <2 years of age are optimal candidates.
- Efficacy: One-time treatment with sustained long-term benefit; Type I patients achieve independent walking when treated early. Comparable or superior efficacy to nusinersen in clinical trials.
- Limitations and Adverse Effects: Delayed-type hypersensitivity reactions, transient liver transaminitis, thrombotic microangiopathy (rare but serious). Liver function monitoring essential. Not suitable for older children/adults due to immune system maturation. Irreversible treatment; future vector therapy precluded.
- Risdiplam (Evrysdi; oral SMN2 splicing modifier):
- Mechanism: Small molecule that increases SMN2 exon 7 inclusion by binding to the SMN2 transcript and promoting productive splicing. Different mechanism than nusinersen but similar functional outcome.
- Administration: Oral daily dosing; more convenient than intrathecal therapy; can be initiated in infants and continued throughout life.
- Efficacy: Benefits all SMA types; particularly useful for patients unable or unwilling to undergo intrathecal procedures. Non-inferiority shown compared to nusinersen in clinical trials.
- Adverse Effects: Generally well-tolerated; potential for transient taste disturbance, some GI symptoms. No hepatotoxicity seen.
- Comparative Considerations:
- Choice among these agents depends on age at diagnosis, disease severity, infrastructure for intrathecal procedures, patient/family preferences, and insurance coverage.
- All three agents are now approved for all SMA types; early initiation is critical given motor neuron loss is progressive.
- Combined therapy being explored in clinical trials but not yet standard practice.
- Supportive and Symptomatic Management:
- Respiratory Support:
- Non-invasive ventilation (bilevel positive airway pressure [BiPAP], continuous positive airway pressure [CPAP]) for sleep-disordered breathing and nocturnal hypoventilation
- Mechanical insufflation-exsufflation (MIE) to assist with clearance of secretions
- Consideration of tracheostomy and long-term mechanical ventilation in advanced cases (though disease-modifying therapies have reduced need for invasive ventilation)
- Sleep studies to monitor for hypoventilation, apnea, and need for respiratory support escalation
- Nutritional and Feeding Support:
- Soft diet modifications, dysphagia precautions, and speech-language pathology consultation
- Gastrostomy tube (G-tube) placement for inadequate oral intake, reduced aspiration risk, and medication administration
- Nutritional optimization to support growth and immune function
- Orthopedic and Physical Medicine Interventions:
- Physical therapy: Passive and active-assisted range-of-motion exercises to maintain joint mobility and prevent contractures; weight-bearing when appropriate
- Occupational therapy: Activities of daily living (ADL) adaptations, assistive devices (walkers, wheelchairs, standing frames)
- Splinting and orthotics: To support joints, prevent contractures, and optimize function
- Scoliosis surveillance and management: Serial imaging; surgical fusion may be indicated for rapidly progressive, severe curves in non-ambulatory patients to preserve respiratory function
- Psychosocial Support and Care Coordination:
- Multidisciplinary SMA care teams (neurology, pulmonology, orthopedics, nutrition, social work, palliative care)
- Genetic counseling for family planning
- Mental health support for patients and families
- Transition planning for adolescents moving to adult care
- Palliative and end-of-life care discussions
- Monitoring During Disease-Modifying Therapy:
- Clinical assessments: Regular evaluation of motor function using validated scales (e.g., Hammersmith Functional Motor Scale Expanded [HFMSE], Children's Upper Limb Functional Scale [CULFS])
- Respiratory function: Serial pulmonary function tests (PFTs), sleep studies
- Laboratory monitoring: Liver function tests (especially with onasemnogene or in early disease-modifying therapy period), complete blood count
- Cardiac function: Baseline and periodic echocardiography (particularly with onasemnogene, which can rarely cause cardiomyopathy)
- Neurofilament biomarkers: Emerging role in monitoring disease progression and treatment response
SMA-related complications and their management include:
- Respiratory Failure and Sleep-Disordered Breathing:
- Progressive diaphragmatic and intercostal muscle weakness leading to restrictive lung disease, hypoventilation (especially during sleep), hypoxemia, and hypercapnia
- Sleep apnea (obstructive and central components) is common and often subclinical; screening with sleep studies is essential
- Management: Tit
- The stem to recognize: a floppy infant who is alert and socially engaged, with tongue fasciculations, absent deep tendon reflexes, belly (paradoxical) breathing with a bell-shaped chest, and intact sensation and normal cognition. The alert, bright-eyed face with profound limb weakness is the classic tell for anterior horn cell disease rather than a central cause.
- Single best next step: send targeted SMN1 exon 7 deletion testing (qPCR/MLPA) — not EMG, not muscle biopsy, not MRI. Genetic confirmation is faster, non-invasive, and diagnostic in ~95%. Reflex SMN2 copy number because it drives prognosis and treatment urgency.
- The association examiners test: SMN2 copy number inversely correlates with severity — more SMN2 copies, more full-length SMN protein, milder phenotype. Every SMN2-directed drug (nusinersen, risdiplam) exploits this by forcing exon 7 inclusion.
- Normal or only mildly elevated CK is the discriminator from myopathy. Markedly elevated CK points to Duchenne muscular dystrophy or Pompe disease instead.
- Common distractors to avoid:
- Infant botulism: also hypotonia and weak cry, but descending weakness with constipation, poor suck, and sluggish/dilated pupils; SMA spares autonomic and pupillary function.
- Pompe disease (acid maltase deficiency): hypotonia plus massive cardiomegaly, macroglossia, and very high CK — cardiomyopathy is not part of untreated SMA.
- Duchenne: X-linked, later onset, calf pseudohypertrophy, huge CK.
- Prader–Willi: neonatal hypotonia and poor feeding but reflexes are present, with dysmorphism and later hyperphagia.
- Eponyms: Type I = Werdnig–Hoffmann; Type III = Kugelberg–Welander.
- Screening and counseling: autosomal recessive, carrier frequency roughly 1 in 50; ACOG recommends offering SMA carrier screening to all patients who are pregnant or planning pregnancy. SMA is on the federal Recommended Uniform Screening Panel, so many affected infants are now identified presymptomatically — treat before symptoms, since lost motor neurons are not recovered.
- Before onasemnogene abeparvovec, check anti-AAV9 antibody titer plus liver enzymes; high titers preclude gene therapy.